EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies

Ze Li, Xiaozhen Wang, Dandan Li, Sheng Cheng, Zhe Li, Heng Guo, Yiwen Dong, Yingming Zheng, Xingang Li

BMC Nephrology · 06.02.2024 · 25 (1)

DOI: 10.1186/s12882-024-03467-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift BMC Nephrology, online erschienen am 06.02.2024. Verfasst von Ze Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, China. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research and application of clinical characteristic diagnosis and treatment technology in Beijing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to investigate the association between cytochrome P450 (CYP) 3A4*22 and cytochrome P450 oxidoreductase (POR)*28 variations and the pharmacokinetics of tacrolimus.

Methods

Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science (SCI), MEDLINE, and Embase were systematically searched from inception to August 2022. The outcomes were weight-adjusted daily dose and dose-adjusted trough concentration (C 0 /Dose).

Results

The study included 2931 renal transplant recipients from 18 publications. Weight-adjusted daily dose of CYP3A4*1/*1 carriers was 0.04 (WMD = 0.04, 95% CI: 0.02 to 0.06), 0.03 (WMD = 0.03, 95% CI: 0.02 to 0.05), 0.02 (WMD = 0.02, 95% CI: 0.01 to 0.03), or 0.02 mg/kg/day (WMD = 0.02, 95% CI: 0.00 to 0.04) higher than CYP3A4*22 carriers in Caucasians at 1 month, 3 months, 6 months, or 12 months post-transplantation. Conversely, C0/Dose was lower for CYP3A4*1/*1 carriers at 3 days (SMD = -0.35, 95% CI: -0.65 to -0.06), 1 month (SMD = -0.67, 95% CI: -1.16 to -0.18), 3 months (SMD = -0.60, 95% CI: -0.89 to -0.31), 6 months (SMD = -0.76, 95% CI: -1.49 to -0.04), or 12 months post-transplantation (SMD = -0.69, 95% CI: -1.37 to 0.00). Furthermore, C 0 /Dose of POR*1/*1 carriers was 22.64 (WMD = 22.64, 95% CI: 2.54 to 42.74) or 19.41 (ng/ml)/(mg/kg/day) (WMD = 19.41, 95% CI: 9.58 to 29.24) higher than POR*28 carriers in CYP3A5 expressers at 3 days or 7 days post-transplantation, and higher in Asians at 6 months post-transplantation (SMD = 0.96, 95% CI: 0.50 to 1.43).

Conclusions

CYP3A4*22 variant in Caucasians restrains the metabolism of tacrolimus, while POR*28 variant in CYP3A5 expressers enhances the metabolism of tacrolimus for renal transplant recipients. However, further well-designed prospective studies are necessary to substantiate these conclusions given some limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusKidney TransplantationHumansCytochrome P-450 CYP3AImmunosuppressive AgentsProspective StudiesPolymorphism, Single NucleotideTransplant RecipientsGenotype

Stichwörter der Autor:innen

Genetic polymorphismsMeta-analysisPharmacokineticsRenal transplant recipientsTacrolimus

Substanzen

TacrolimusCytochrome P-450 CYP3AImmunosuppressive AgentsCYP3A4 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, China.
  • Central Laboratory, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, China. lxg198320022003@163.com.

Förderung

  • Research and application of clinical characteristic diagnosis and treatment technology in Beijing

Zitieren

APA

Li, Z., Wang, X., Li, D., Cheng, S., Li, Z., Guo, H., Dong, Y., Zheng, Y., & Li, X. (2024). Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies. BMC Nephrology, 25(1). https://doi.org/10.1186/s12882-024-03467-4

Vancouver

Li Z, Wang X, Li D, Cheng S, Li Z, Guo H, et al. Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies. BMC Nephrology. 2024;25(1). doi:10.1186/s12882-024-03467-4

BibTeX
@article{Li2024,
  author = {Li, Ze and Wang, Xiaozhen and Li, Dandan and Cheng, Sheng and Li, Zhe and Guo, Heng and Dong, Yiwen and Zheng, Yingming and Li, Xingang},
  title = {Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies},
  journal = {BMC Nephrology},
  year = {2024},
  volume = {25},
  number = {1},
  doi = {10.1186/s12882-024-03467-4}
}
Kostenlos starten →